BLU-808 for Allergic Rhinoconjunctivitis
Trial Summary
Do I need to stop taking my current medications for the trial?
Yes, you will need to stop taking any medications for ragweed or other allergy symptoms, as well as any medications that could affect your safety or interfere with the study results.
What data supports the effectiveness of the drug BLU-808 for treating allergic rhinoconjunctivitis?
The research indicates that leukotriene receptor antagonists, like ICI 204,219, can relieve symptoms of allergic rhinitis, which is similar to allergic rhinoconjunctivitis. Additionally, combining leukotriene receptor antagonists with intranasal corticosteroids has been shown to be effective in treating allergic rhinitis, suggesting potential benefits for BLU-808 if it has similar components.12345
What is the purpose of this trial?
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants with ragweed (Ambrosia artemisiifolia)-induced allergic rhinoconjunctivitis (ARC). Participants will undergo eligibility assessments that include exposure to ragweed pollen in an allergen exposure chamber (AEC).
Eligibility Criteria
Adults over 18 with a history of ragweed-induced allergic rhinoconjunctivitis (ARC) for more than two years, who have had a positive skin test for ragweed. Participants must show significant nasal and eye symptoms from ARC to join the study.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BLU-808 or placebo orally for 28 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BLU-808
Find a Clinic Near You
Who Is Running the Clinical Trial?
Blueprint Medicines Corporation
Lead Sponsor